"NNVC is a more compelling buy today at $0.65 then it was when I first mentioned it here at $0.10, before it ran to $3.75. Then, it was pure speculation. Now, it has taken its first steps as a genuine biotechnology company."What about today, 60 days later, with the price up at $1.60?
Here is a post by the same advocate of these shares that I used in my April blog and who is probably more knowledgeable about Nanoviricides then anyone outside of the company's CEO and Chairman of the Board.
"In the next 5 years I'm expecting a 100 to 500 bagger from current prices. Simple matter of doing the math on approval and stockpiling of drugs for Influenza, HIV, EKC and HEP B and C.
Influenza = $3 billion
HIV = $3 billion
EKS = $3 bilion
HEP B & C = $3 billion
"15% royalty for NNVC = $1.8 billion with a multiplier of 25 times earnings leaves a market cap of $45 billion or $300 a share. Now throw in one drug approval every 6 months and what do you get?"
Takeaway: In the past sixty days the trickle of news out of NNVC has caused someone who knows more about the company then either you or I to raise his valuation of the company by 50%, about another $100 per share.